Healthtech firm raises £2m as pandemic boosts demand for patient app

Funding | Latest News | Technology | Yorkshire
Pix: Shaun Flannery/shaunflanneryphotography.com
L-R Sally Abbatt, Bob Gomersall, John Eaglesham of ADI and Jonathan Sharp of Mercia.

A healthtech business with an app that helps patients communicate with clinicians remotely has raised a further £2m to help expand its use.

Advanced Digital Innovation (ADI) has raised funding from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, the UK government’s Future Fund and the company’s Chair and founder Bob Gomersall.

The Yorkshire-based company says the pandemic has boosted interest in its MyPathway app, which removes the need for appointment letters and calls, allowing patients to agree care plans with clinicians, who can then monitor their progress and receive feedback.

Over 55,000 patients are now signed up to the system, which is already used in hospitals in Sheffield, the North West and Essex, and most recently has been adopted in Leeds. The company has completed a successful initial trial in Northern Ireland.

The investment will allow ADI to enhance the product to make it easier for patients to sign up remotely and to achieve further accreditations to extend its use in other areas of the NHS. The company, which currently employs 15 staff, is planning to create 20 new jobs at its headquarters in Saltaire in the next 12 months.

John Eaglesham, CEO, said: “MyPathway has really proved its worth during the lockdown. With routine appointments having to be cancelled, it has made it so much easier for hospitals to communicate with patients and keep track of their condition.

“The pandemic has also led to a major shift in mindset as clinicians and GPs recognise there is not always a need to see patients in person and are more open to new technology. Ultimately this will lead to lower costs and, since MyPathway increases feedback from patients, will allow better evaluation of care pathways and more effective treatment.”

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment

Your email address will not be published. Required fields are marked *